The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Concepts and Core Principles of Fragment-Based Drug Design
Open accessAbstract
In this review, a general introduction to fragment-based drug design and the underlying concepts is given. General considerations and methodologies ranging from library selection/construction over biophysical screening and evaluation methods to in-depth hit qualification and subsequent optimization strategies are discussed. These principles can be generally applied to most classes of drug targets. The examples given for fragment growing, merging, and linking strategies at the end of the review are set in the fields of enzyme-inhibitor design and macromolecule–macromolecule interaction inhibition. Building upon the foundation of fragment-based drug discovery (FBDD) and its methodologies, we also highlight a few new trends in FBDD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Proteome-wide covalent ligand discovery in native biological systems
Backus, K. M., Correia, B. E., Lum, K. M., Forli, S., Horning, B. D., González-Páez, G. E., Chatterjee, S., Lanning, B. R., Teijaro, J. R., Olson, A. J., et al. (2016) · Nature · doi:10.1038/nature18002 · Cited by 940 · cited 1×
“have described the use of a chemical proteomic method in order to perform fragment-based ligand discovery in native biological systems [21].”
MethodOral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835 · cited 1×
“Importantly, it has to be noted that eventual drugs and clinical candidates can still have good bioavailability, whilst violating the Lipinski rules [19].”
Background
Cited by
Protein X-ray Crystallography and Drug Discovery
Maveyraud, L., & Mourey, L. (2020) · Molecules · doi:10.3390/molecules25051030 · Cited by 269
Structure-Based Drug Design with a Deep Hierarchical Generative Model
Weller, J. A., & Rohs, R. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01193 · Cited by 47
Nordquist, E. B., Zhao, M., Kumar, A., & MacKerell, A. D. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01189 · Cited by 15
Wranik, M., Kepa, M. W., Beale, E. V., James, D., Bertrand, Q., Weinert, T., Furrer, A., Glover, H., Gashi, D., Carrillo, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43523-5 · Cited by 14
Structural Insight into Geranylgeranyl Diphosphate Synthase (GGDPS) for Cancer Therapy
Pham, A. C., Holstein, S. A., & Borgstahl, G. E. O. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0358 · Cited by 9
Metadata
- Authors
- Kirsch, P., Hartman, A. M., Hirsch, A. K. H., & Empting, M.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2019-11-26
- Volume
- 24
- Issue
- 23
- Pages
- 4309
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2991090734
- Cited by
- 232
- References
- 3
- FWCI
- 11.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Concepts and Core Principles of Fragment-Based Drug Design. https://app.cochat.ai/papers/10.3390/molecules24234309
- The paper
- Kirsch, P., Hartman, A. M., Hirsch, A. K. H., & Empting, M. (2019). Concepts and Core Principles of Fragment-Based Drug Design. Molecules. https://doi.org/10.3390/molecules24234309
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.